Biohaven to Raise $125M from Janus Henderson Share Sale

Biohaven Pharmaceuticals has agreed to sell 12.5 million common shares to Janus Henderson Investors at $10.00 per share, generating expected gross proceeds of $125 million. The sale is a block transaction, with the shares being issued to the investor.